Pricing Log in Create free account
Friday 6 November 2026 Export NGNE’s income statement to Excel — free account

Neurogene Inc.

NGNE Healthcare Biotechnology

Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00.

EPS
−45.7%
Free cash flow
−23.0%
Total debt
−66.7%

Quarter to June 2026, against a year earlier

25.29 0.36 −1.40%
Market cap
$513.3M
P/E
0.0×
Fwd P/E
−4.5×
Dividend yield
—
F-score
n/a
Altman Z
8.68
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 1.13
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — 1 5 — 1 — 2 — — — —
Insider Ownership 25.68%

Capital & Financial Ratios $m

Size
Market Cap 513.29
Revenue ttm —
Net income ttm (111.11)
Free cash flow ttm (87.71)
Net debt Q (225.39)
Valuation
P/E 0.00
Forward P/E (4.45) (negative: loss-making)
Price / sales 0.00
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.63
Financial health
Current ratio Q 10.64 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (27,530.00)
Growth
Revenue growth Q —
Operating income growth Q −40.60% (below 0%: shrinking)
EPS, this year −32.92% (below 0%: weak)
EPS, next year A +7.28%
Revenue, next year A −16.67% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A −3.15% (below 0%: weak)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

P/B against its own 10 years 67.94%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 197 312 269 225
Receivables — — — —
Inventory — — — —
Other 3 4 3 4
200 316 272 229
2023 2024 2025 Q'26
Payables 3 1 2 3
ST’ Debt — — — —
Other — — — —
23 15 16 22

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 9.34% 6.74% 39.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −1.40 Actual −1.53

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −1.26 −0.99 Beat by 0.27
Q4 FY25 −1.20 −1.12 Beat by 0.08
Q1 FY26 −1.35 −1.39 Miss by 0.04
Q2 FY26 −1.40 −1.53 Miss by 0.13
Q3 FY26 −1.49 — Reports 12 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (1.39) (1.53) — — —
’25 (1.08) (1.05) (0.99) (1.12) (4.24)
’24 (1.00) (1.09) (1.19) (0.99) (4.28)
’23 (28.26) (26.71) (32.68) — (7.80)
’22 (5.60) (5.60) (4.80) (4.80) (139.72)
’21 (5.40) (5.40) (5.60) (5.60) (22.00)
’20 (3.60) (4.00) (0.80) (4.80) (12.80)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 — 1 — — 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (26) (24) — — —
’25 (21) (19) (20) (17) (77)
’24 (22) (16) (16) (17) (71)
’23 (14) (9) (12) (17) (51)
’22 (14) (11) (9) (18) (53)
’21 (13) (13) (9) (12) (48)
’20 (6) (9) 0 (9) (25)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (26) (24) — — —
’25 (22) (20) (20) (18) (78)
’24 (22) (16) (16) (18) (71)
’23 (14) (9) (12) (17) (52)
’22 (15) (12) (10) (19) (55)
’21 (14) (14) (9) (13) (51)
’20 (7) (10) (1) (10) (27)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — — 25 — — — — — 1 — — (42.3%) 61 61 61 0.0%
Gross margin, % — — 100.00 0.00 0.00 0.00 0.00 — 100.00 — 0.00 0.0 pt
EBT (37) (50) (32) (69) (33) (61) (55) (36) (75) (90) (111) +10.4%
EBT margin, % 0.00 0.00 (126.34) 0.00 0.00 0.00 0.00 0.00 (8,123.68) 0.00 0.00 0.0 pt
Net income (37) (50) (32) (69) (33) (61) (55) (36) (75) (90) (111) +10.4%
Per share, $
Per share, $ Revenue 0.00 0.00 21.26 0.00 0.00 0.00 0.00 0.00 0.05 0.00 0.00 n/m
Earnings (39.20) (42.80) (26.80) (51.40) (12.80) (22.00) (139.72) (73.81) (4.28) (4.24) (5.03) (21.9%)
Cash flow (32.00) (38.14) (26.85) (11.39) (9.48) (17.28) (133.73) (104.52) (4.02) (3.62) (3.85) (21.5%)
Capex (0.75) (0.42) (0.04) (0.65) (0.86) (1.19) (5.65) (0.65) (0.05) (0.06) (0.04) (25.2%)
Free cash flow (32.75) (38.56) (26.89) (12.04) (10.34) (18.47) (139.38) (105.17) (4.07) (3.67) (3.89) (21.6%)
Book value 153.13 84.34 61.80 104.84 73.79 51.91 249.69 378.10 17.67 12.42 9.63 (24.4%)
Shares, m 1 1 1 1 3 3 0 0 18 21 22 +41.4%
Valuation, ×
Valuation, × P/E — — 0.00 — — — — — 0.00 — 0.00 0.0
P/S — — 0.00 — — — — — 0.00 — 0.00 0.0
P/B — — 0.70 — — — — — 1.29 — 2.63 1.0
EV/Sales — — 0.00 — — — — — 0.00 — 0.00 0.0
EV/FCF — — 0.83 — — — — — (1.25) — (3.93) (0.2)
Cash, $m
Cash, $m Operating cash flow (30) (45) (32) (15) (25) (48) (53) (51) (71) (77) (87) +11.0%
Capex (1) 0 0 (1) (2) (3) (2) 0 (1) (1) (1) +5.8%
Free cash flow (31) (45) (32) (16) (27) (51) (55) (52) (71) (78) (88) +10.9%
Balance, $m
Balance, $m Working capital 94 98 73 139 187 135 78 177 301 255 207 +11.7%
Net debt (103) (108) (77) (143) (192) (142) (82) (197) (312) (269) (225) +11.3%
Shareholders’ equity 145 99 73 142 191 143 99 186 310 265 217 +7.0%
Returns, %
Returns, % ROA (27.64) (37.92) (33.61) (61.82) (18.61) (32.47) (40.50) (21.89) (26.92) (28.94) (41.02) (1.3) pt
ROIC (56.49) 0.00 0.00 0.00 0.00 (8,175.92) (211.87) 0.00 0.00 0.00 0.00 +56.5 pt
ROE (29.24) (41.21) (36.82) (64.79) (19.99) (36.33) 3,839.23 (180.30) (30.28) (31.41) (45.32) (2.2) pt
People
People Employees 38 51 8 36 70 91 56 91 107 131 — +14.7%
Revenue/emp, $m 0.00 0.00 3.13 0.00 0.00 0.00 0.00 0.00 0.01 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Jun 2024 · fundamentals updated 26 Oct 2026

Neurogene Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR $524.8M — (loss-making) — (loss-making) −7.53% (below 0%: shrinking) n/m −31.52% (below 0%: shrinking) 0.00% 0.00% Compare
ENTX Entera Bio Ltd. $520.0M — (loss-making) — (loss-making) +200.00% (above 0%: growing) n/m −108.86% (below 0%: shrinking) 0.00% 0.00% Compare
FTH Faeth Therapeutics, Inc. $514.8M — (loss-making) — — n/m −262.66% (below 0%: shrinking) 0.00% 0.00% Compare
NGNE Neurogene Inc. $513.3M — (loss-making) — (loss-making) — n/m −22.97% (below 0%: shrinking) 100.00% 0.00%
CLYM Climb Bio, Inc. $509.5M — (loss-making) — — n/m +3.73% (above 0%: growing) — 0.00% Compare
YDES YD Bio Limited $508.7M — — — — — — — Compare
SLBT SL SCIENCE HLDG $504.7M — — — — — — — Compare
PBYI Puma Biotechnology, Inc. $504.3M 15.3× 24.2× +7.75% (above 0%: growing) +33.33% (above 0%: growing) −88.45% (below 0%: shrinking) 77.92% 13.42% Compare
OVID Ovid Therapeutics $503.9M — (loss-making) — (loss-making) +463.85% (above 0%: growing) n/m −268.54% (below 0%: shrinking) 100.00% (2,141.61%) Compare
Median of peers $509.1M — — +103.88% — −98.65% 0.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 16 April 2026

Ownership

Directors and executive officers, together 11.68%
Samsara BioCapital, L.P. 11.07%
Entities affiliated with Baker Brothers Investments 9.99%
Entities affiliated with EcoR1 Capital Fund, L.P. 9.99%
Entities affiliated with Redmile Group, LLC 9.99%
Entities affiliated with RTW Investments, LP 9.99%
Rachel McMinn 9.06%
Entities affiliated with Casdin Capital, LLC 8.29%
Entities affiliated with BlackRock Capital Management, Inc. 5.99%
Entities affiliated with Trails Edge Capital Partners, LP 5.02%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Neurogene Inc. (NGNE) Latest News

27 Oct

Impact 4 · · Business Wire

20 Oct

Impact 4 · · Business Wire

11 Aug

Impact 4 ·
Impact 3 ·
Impact 3 ·

1 Jul

Impact 3 ·

30 Jun

Impact 4 · · Business Wire
Impact 3 ·

29 Jun

Impact 4 ·

8 Jun

Impact 4 · · Business Wire

12 May

Impact 4 · · Business Wire
Impact 3 · · Business Wire

20 Apr

Impact 4 ·

24 Mar

Impact 4 · · Business Wire
Impact 3 · · Associated Press Finance

21 Mar

Impact 4 · · MarketBeat

26 Feb

Impact 4 ·

14 Feb

Impact 4 · · MarketBeat

12 Jan

Impact 4 · · Business Wire

5 Jan

Impact 3 · · Business Wire

26 Nov

Impact 4 · · Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.

13 Nov

Impact 4 · · Business WireClinical Trials ArenaMT NewswiresAssociated Press FinanceGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.com
Impact 3 · · Associated Press Finance

12 Nov

Impact 4 ·

6 Nov

Impact 4 · · Business Wire

9 Oct

Impact 4 · · Business Wire

5 Sep

Impact 3 · · Business Wire

20 Aug

Impact 3 ·

30 Jul

Impact 4 · · Simply Wall St.

19 Jun

Impact 4 ·
stockrow.com/NGNE · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com